Curative resection of borderline resectable perihilar cholangiocarcinoma following neoadjuvant gemcitabine and cisplatin plus durvalumab immunochemotherapy: a case report
Shogo Tanaka, Hiroshi Tsukuda, Takuma Okada, Akihiro Tanaka, Ryugo Sawada, Kiyotaka Yukimoto, Yutaka Tamamori, Yuichi Fumimoto, Shinsuke Hiramatsu, Yoshio Ohta · 2026
Read Curative resection of borderline resectable perihilar cholangiocarcinoma following neoadjuvant gemcitabine and cisplatin plus durvalumab immunochemotherapy: a case report by Shogo Tanaka, Hiroshi Tsukuda, Takuma Okada, Akihiro Tanaka, Ryugo Sawada, Kiyotaka Yukimoto, Yutaka Tamamori, Yuichi Fumimoto, Shinsuke Hiramatsu, Yoshio Ohta (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13082388.txt.
Description
Postoperative survival benefits of neoadjuvant gemcitabine and cisplatin plus durvalumab (GCD) immunochemotherapy for biliary tract cancers, which meet the criteria for borderline resectability, remain limited. A 75-year-old male presented to our hospital with epigastric pain. Diagnostic imaging demonstrated perihilar cholangiocarcinoma invading the right hepatic artery with lymph node metastasis.
Catalog record
| CREATOR | Shogo Tanaka, Hiroshi Tsukuda, Takuma Okada, Akihiro Tanaka, Ryugo Sawada, Kiyotaka Yukimoto, Yutaka Tamamori, Yuichi Fumimoto, Shinsuke Hiramatsu, Yoshio Ohta |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |